Timothy Perren
Overview
Explore the profile of Timothy Perren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oswald A, Symeonides S, Wheatley D, Chan S, Brunt A, McAdam K, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(1):35-46.
PMID: 36859649
Purpose: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and...
2.
Berdunov V, Millen S, Paramore A, Hall P, Perren T, Brown R, et al.
J Med Econ
. 2022 Apr;
25(1):591-604.
PMID: 35416089
Aims: Given the high rate of adverse events and high cost of adjuvant chemotherapy, it is optimal to avoid its use when endocrine therapy is equally effective at preventing distant...
3.
You B, van Wagensveld L, Tod M, Sonke G, Horlings H, Kruitwagen R, et al.
Br J Cancer
. 2022 Apr;
127(1):79-83.
PMID: 35361918
Background: In ovarian carcinomas, the likelihood of disease cure following first-line medical-surgical treatment has been poorly addressed. The objective was to: (a) assess the likelihood of long-term disease-free (LDF) > ...
4.
Blagden S, Cook A, Poole C, Howells L, McNeish I, Dean A, et al.
Lancet Oncol
. 2020 Jul;
21(7):969-977.
PMID: 32615110
Background: The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8...
5.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt A, Nemsadze G, et al.
J Clin Oncol
. 2019 Dec;
38(5):423-433.
PMID: 31841354
Purpose: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has...
6.
Hollis R, Churchman M, Michie C, Rye T, Knight L, McCavigan A, et al.
Cancer
. 2019 Jun;
125(16):2772-2781.
PMID: 31154673
Background: Approximately half of high-grade serous ovarian carcinomas (HGSOCs) demonstrate homologous recombination repair (HR) pathway defects, resulting in a distinct clinical phenotype comprising hypersensitivity to platinum, superior clinical outcome, and...
7.
Gore M, Hackshaw A, Brady W, Penson R, Zaino R, McCluggage W, et al.
Gynecol Oncol
. 2019 Apr;
153(3):541-548.
PMID: 31005287
Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC:...
8.
Kommoss S, Winterhoff B, Oberg A, Konecny G, Wang C, Riska S, et al.
Clin Cancer Res
. 2017 Feb;
23(14):3794-3801.
PMID: 28159814
Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has...
9.
Wallington M, Saxon E, Bomb M, Smittenaar R, Wickenden M, McPhail S, et al.
Lancet Oncol
. 2016 Sep;
17(9):1203-16.
PMID: 27599138
Background: 30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this indicator are limited. The Systemic Anti-Cancer Therapy (SACT) dataset...
10.
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial
Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M
Value Health
. 2016 Jun;
19(4):431-9.
PMID: 27325335
Background: Bevacizumab is used extensively in the treatment of cancer, including advanced ovarian cancer, for which results of the International Collaborative Ovarian Neoplasm (ICON) 7 trial have been recently reported....